{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=101",
    "query": {
      "condition": "Relapsed/Refractory",
      "page": 101
    },
    "page_size": 10
  },
  "pagination": {
    "page": 101,
    "page_size": 10,
    "total_count": 3666,
    "total_pages": 367,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=102&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=100&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T21:47:06.112Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01253369",
      "title": "Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Lung Cancer",
        "SCLC"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2010-06",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-11-16T21:47:06.112Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01253369"
    },
    {
      "nct_id": "NCT00295841",
      "title": "Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "clofarabine",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 53,
      "start_date": "2005-02",
      "completion_date": "2015-01-07",
      "has_results": false,
      "last_update_posted_date": "2018-08-10",
      "last_synced_at": "2026-11-16T21:47:06.112Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295841"
    },
    {
      "nct_id": "NCT00022451",
      "title": "Tipifarnib in Treating Young Patients With Refractory Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": null,
      "start_date": "2001-06",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-11-16T21:47:06.112Z",
      "location_count": 56,
      "location_summary": "Little Rock, Arkansas • Duarte, California • La Jolla, California + 46 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022451"
    },
    {
      "nct_id": "NCT06594445",
      "title": "HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloid Malignancy",
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "GTB-360",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2024-11-19",
      "completion_date": "2027-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-16T21:47:06.112Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06594445"
    },
    {
      "nct_id": "NCT00372619",
      "title": "Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "clofarabine",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 74,
      "start_date": "2007-03",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2017-06-05",
      "last_synced_at": "2026-11-16T21:47:06.112Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Downey, California • Long Beach, California + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00372619"
    },
    {
      "nct_id": "NCT00515892",
      "title": "Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Non-Hodgkin's Lymphoma",
        "NHL"
      ],
      "interventions": [
        {
          "name": "Immunotoxin therapy",
          "type": "DRUG"
        },
        {
          "name": "CAT-8015 Immunotoxin",
          "type": "DRUG"
        },
        {
          "name": "Biological therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Antibody Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Monoclonal Antibody Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Cambridge Antibody Technology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2007-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-08-14",
      "last_synced_at": "2026-11-16T21:47:06.112Z",
      "location_count": 2,
      "location_summary": "Beverly Hills, California • Bethesda, Maryland",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515892"
    },
    {
      "nct_id": "NCT01657331",
      "title": "Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "Anaplastic Large Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Neulasta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2012-07",
      "completion_date": "2018-06",
      "has_results": true,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-11-16T21:47:06.112Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01657331"
    },
    {
      "nct_id": "NCT07847957",
      "title": "Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)",
        "Refractory Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Roginolisib",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2027-01-13",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-16T21:47:06.112Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07847957"
    },
    {
      "nct_id": "NCT02064387",
      "title": "Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "GSK2857916",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2014-07-29",
      "completion_date": "2019-08-01",
      "has_results": true,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-11-16T21:47:06.112Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • New York, New York • Chapel Hill, North Carolina + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02064387"
    },
    {
      "nct_id": "NCT00309907",
      "title": "Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Acute Myeloid Leukemia in Remission",
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Myelodysplastic Syndromes",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Disseminated Neuroblastoma",
        "Juvenile Myelomonocytic Leukemia",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Previously Treated Myelodysplastic Syndromes",
        "Pulmonary Complications",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Neuroblastoma",
        "Recurrent Wilms Tumor and Other Childhood Kidney Tumors",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "etanercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2006-04",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2017-09-29",
      "last_synced_at": "2026-11-16T21:47:06.112Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00309907"
    }
  ]
}